SCHEDULE: Vanguard Group Reports 0% Zevra Therapeutics Stake

The Vanguard Group has reported a 0% beneficial ownership in Zevra Therapeutics Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 2 to its Schedule 13G for Zevra Therapeutics Inc. common stock.
• The filing indicates that The Vanguard Group now holds 0% beneficial ownership of Zevra Therapeutics Inc.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries and business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately on a disaggregated basis.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated entities.
• The subsidiaries and business divisions continue to pursue the same investment strategies as previously pursued by The Vanguard Group, Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Zevra Therapeutics, as the change in beneficial ownership reporting by The Vanguard Group is due to internal corporate realignment rather than a direct investment decision regarding Zevra's performance or outlook.

Future Outlook

NA

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine for institutional investors like The Vanguard Group, particularly when their beneficial ownership crosses certain thresholds or, as in this case, when internal corporate restructuring impacts reporting requirements. This specific filing reflects a change in reporting structure rather than a strategic divestment from Zevra Therapeutics by Vanguard's overall managed assets.

Stakeholder Impact

• Shareholders of Zevra Therapeutics: May initially perceive a large institutional investor's exit, but understanding it is a reporting change due to internal realignment should mitigate concerns. The overall managed assets by Vanguard may still hold Zevra shares through other entities.
• The Vanguard Group: Streamlines internal reporting and compliance by disaggregating beneficial ownership among subsidiaries.

Key Dates

Recommendation

The filing primarily details a change in The Vanguard Group's internal reporting structure, resulting in a 0% beneficial ownership reported for the parent entity. This is not indicative of a strategic divestment from Zevra Therapeutics by Vanguard's broader managed funds, but rather a technical adjustment in how ownership is attributed. Therefore, it provides no new fundamental information to warrant a change in investment recommendation for Zevra Therapeutics, suggesting a 'hold' position for existing investors.

Keywords

Zevra Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Ownership, Investment Management, Realignment